Fixed combination of oral antidiabetics for the effective and safe glycemic control in type 2 diabetic patients
Type 2 diabetes mellitus is associated with hyperglycemia and atherogenic risk. Thus, hypoglycemic therapy should ensure both efficacy and safety regarding the prevention of micro- and macrovascular complications. To improve glycemic control in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin combination treatment with both agents should be recommended. Glimekomb® (fixed combination of metformin and sulfonylurea derivative gliclazide) is an effective, safe and cost-effective drug promoting attainment of diabetes treatment goals.